The Childhood Solid Tumor Network: A new resource for the developmental biology and oncology research communities.

[1]  A. Pappo,et al.  Pediatric solid tumor genomics and developmental pliancy , 2015, Oncogene.

[2]  Li Ding,et al.  The Genomic Landscape of Childhood and Adolescent Melanoma , 2014, The Journal of investigative dermatology.

[3]  Erin K. Hedlund,et al.  Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations. , 2014, Cancer discovery.

[4]  Li Ding,et al.  Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma. , 2014, Cell reports.

[5]  F. Berthold,et al.  Neuroblastoma in older children, adolescents and young adults: A report from the International Neuroblastoma Risk Group project , 2014, Pediatric blood & cancer.

[6]  Heather L. Mulder,et al.  Targeting oxidative stress in embryonal rhabdomyosarcoma. , 2013, Cancer cell.

[7]  Michael A. Dyer,et al.  Neuroblastoma: developmental biology, cancer genomics and immunotherapy , 2013, Nature Reviews Cancer.

[8]  D. Finkelstein,et al.  Cross-species genomic and epigenomic landscape of retinoblastoma , 2013, Oncotarget.

[9]  Jenine K. Harris,et al.  Incidence of Childhood and Adolescent Melanoma in the United States: 1973–2009 , 2013, Pediatrics.

[10]  F. Speleman,et al.  MYCN and ALKF1174L are sufficient to drive neuroblastoma development from neural crest progenitor cells , 2013, Oncogene.

[11]  Giovanni Parmigiani,et al.  Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma , 2012, Nature Genetics.

[12]  L. Spector,et al.  The epidemiology of hepatoblastoma , 2012, Pediatric blood & cancer.

[13]  J. Graff,et al.  A mouse model of rhabdomyosarcoma originating from the adipocyte lineage. , 2012, Cancer cell.

[14]  R. Stallings,et al.  LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression , 2012, Nature Genetics.

[15]  Li Ding,et al.  The Pediatric Cancer Genome Project , 2012, Nature Genetics.

[16]  Mauro Delorenzi,et al.  PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  D. Neuberg,et al.  Activated ALK collaborates with MYCN in neuroblastoma pathogenesis. , 2012, Cancer cell.

[18]  Jinghui Zhang,et al.  Association of age at diagnosis and genetic mutations in patients with neuroblastoma. , 2012, JAMA.

[19]  M. Ladanyi,et al.  Molecular pathogenesis of Ewing sarcoma: new therapeutic and transcriptional targets. , 2012, Annual review of pathology.

[20]  Matthew W. Wilson,et al.  A Novel Retinoblastoma Therapy from Genomic and Epigenetic Analyses , 2011, Nature.

[21]  U. Dirksen,et al.  Risk of recurrence and survival after relapse in patients with Ewing sarcoma , 2011, Pediatric blood & cancer.

[22]  J. Sage,et al.  Coexpression of normally incompatible developmental pathways in retinoblastoma genesis. , 2011, Cancer cell.

[23]  J. Neuhaus,et al.  Clinical features and outcomes in patients with extraskeletal ewing sarcoma , 2011, Cancer.

[24]  J. Maris.  Recent advances in neuroblastoma. , 2010, The New England journal of medicine.

[25]  O. Delattre,et al.  Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  S. Ognjanovic,et al.  Trends in childhood rhabdomyosarcoma incidence and survival in the United States, 1975‐2005 , 2009, Cancer.

[27]  P. Gunaratne,et al.  Histologic subtypes of hepatoblastoma are characterized by differential canonical Wnt and Notch pathway activation in DLK+ precursors. , 2009, Human pathology.

[28]  S. Ogawa,et al.  Oncogenic mutations of ALK kinase in neuroblastoma , 2008, Nature.

[29]  John M. Maris,et al.  Identification of ALK as a major familial neuroblastoma predisposition gene , 2008, Nature.

[30]  D. Gary Gilliland,et al.  Activating mutations in ALK provide a therapeutic target in neuroblastoma , 2008, Nature.

[31]  F. Alt,et al.  Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease. , 2008, Genes & development.

[32]  J. Maris,et al.  Prevalence and functional consequence of PHOX2B mutations in neuroblastoma , 2008, Oncogene.

[33]  M. Dyer,et al.  Retinoblastoma: from the two-hit hypothesis to targeted chemotherapy. , 2007, Cancer research.

[34]  M. Washington,et al.  Protocol for the examination of specimens from pediatric patients with hepatoblastoma. , 2007, Archives of pathology & laboratory medicine.

[35]  M. Dyer,et al.  Neuronal differentiation and synaptogenesis in retinoblastoma. , 2007, Cancer research.

[36]  M. Hicks,et al.  Clinicopathologic features of osteosarcoma in patients with Rothmund-Thomson syndrome. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  W. Furman,et al.  Familial adenomatous polyposis in two brothers with hepatoblastoma: Implications for diagnosis and screening , 2006, Pediatric blood & cancer.

[38]  K K Matthay,et al.  Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  B. Pollock,et al.  The spectrum of APC mutations in children with hepatoblastoma from familial adenomatous polyposis kindreds. , 2005, The Journal of pediatrics.

[40]  T. Fears,et al.  Pediatric melanoma: risk factor and survival analysis of the surveillance, epidemiology and end results database. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  M. Tucker,et al.  Risk of new cancers after radiotherapy in long-term survivors of retinoblastoma: an extended follow-up. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  A. Munnich,et al.  PHOX2B genotype allows for prediction of tumor risk in congenital central hypoventilation syndrome. , 2005, American journal of human genetics.

[43]  M. Dyer,et al.  The search for the retinoblastoma cell of origin , 2005, Nature Reviews Cancer.

[44]  E. Rappaport,et al.  Germline PHOX2B mutation in hereditary neuroblastoma. , 2004, American journal of human genetics.

[45]  Jonathan Gray,et al.  Rb regulates proliferation and rod photoreceptor development in the mouse retina , 2004, Nature Genetics.

[46]  A. Pappo.  Melanoma in children and adolescents. , 2003, European journal of cancer.

[47]  G. Brodeur.  Neuroblastoma: biological insights into a clinical enigma , 2003, Nature Reviews Cancer.

[48]  Charles J. Sherr,et al.  The INK4a/ARF network in tumour suppression , 2001, Nature Reviews Molecular Cell Biology.

[49]  James R. Anderson,et al.  Rhabdomyosarcoma and Undifferentiated Sarcoma in the First Two Decades of Life: A Selective Review of Intergroup Rhabdomyosarcoma Study Group Experience and Rationale for Intergroup Rhabdomyosarcoma Study V , 2001, Journal of pediatric hematology/oncology.

[50]  J. Foley,et al.  Beta-catenin mutations and protein accumulation in all hepatoblastomas examined from B6C3F1 mice treated with anthraquinone or oxazepam. , 2000, Cancer research.

[51]  F. Barr.  Chromosomal translocations involving paired box transcription factors in human cancer. , 1997, The international journal of biochemistry & cell biology.

[52]  G. Mohapatra,et al.  Targeted expression of MYCN causes neuroblastoma in transgenic mice , 1997, The EMBO journal.

[53]  W. McWhirter,et al.  Risk factors for childhood melanoma in Queensland, Australia , 1997, International journal of cancer.

[54]  C. Cepko,et al.  Cell fate determination in the vertebrate retina. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[55]  S. Friend,et al.  Germline mutations of the p53 tumor suppressor gene in children with osteosarcoma. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  A. Huvos,et al.  Osteogenic sarcoma with clinically detectable metastasis at initial presentation. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  G. Thomas,et al.  Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours , 1992, Nature.

[58]  D. Slamon,et al.  Frequency and structure of p53 rearrangements in human osteosarcoma. , 1990, Cancer research.

[59]  C. Sapienza,et al.  A model for embryonal rhabdomyosarcoma tumorigenesis that involves genome imprinting , 1989 .

[60]  R. Ellsworth,et al.  Second tumors in nonirradiated bilateral retinoblastoma. , 1979, American journal of ophthalmology.

[61]  D. L. Stewart,et al.  Receptive field characteristics of striate cortical neurons in the rabbit. , 1971, Brain research.

[62]  Robert W. Williams,et al.  Eye, retina, and visual system of the mouse , 2008 .

[63]  L. Ries,et al.  Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995. , 1999 .

[64]  G. Perilongo,et al.  Liver tumours. Commentary , 1999 .

[65]  H. Shimada,et al.  Histopathology of childhood sarcomas, Intergroup Rhabdomyosarcoma Studies I and II: clinicopathologic correlation. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.